arrow_back Trending Legislation
Share share

Increased Generic Drug Transparency: Faster Access to Information

New rules aim to make it easier for generic drug companies to get key information from the government agency. This could speed up the process of bringing cheaper drug alternatives to market, potentially lowering healthcare costs for citizens.
Key points
Generic drug companies can now ask the government agency if their product is qualitatively and quantitatively the same as the original drug.
The agency must disclose if the generic drug's composition differs from the original, specifying ingredients and deviations.
Once a determination of sameness is made, the agency cannot change it unless the original drug was withdrawn for safety/effectiveness or an error is found.
The agency will issue guidelines on how it determines drug sameness, increasing predictability for manufacturers.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Introduced
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Increasing Transparency in Generic Drug Applications Act
Print number: S 1302
Sponsor: Sen. Hassan, Margaret Wood [D-NH]
Process start date: 2025-04-03
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about Increased Generic Drug Transparency: Faster Access to Information

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is S 1302.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2025-04-03.

What are the main provisions?

Key points include:

  • Generic drug companies can now ask the government agency if their product is qualitatively and quantitatively the same as the original drug.
  • The agency must disclose if the generic drug's composition differs from the original, specifying ingredients and deviations.
  • Once a determination of sameness is made, the agency cannot change it unless the original drug was withdrawn for safety/effectiveness or an error is found.
  • The agency will issue guidelines on how it determines drug sameness, increasing predictability for manufacturers.

What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Hassan, Margaret Wood [D-NH].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-23.

Analysis and Potential Impact of S 1302

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health